KRAS and non-small cell lung carcinoma: Definitely patients with PD-L1>50% and KRAS-mutant NSCLC had favorable survival (mOS ≥20 months) with either ICI monotherapy or chemoimmunotherapy, while patients with KRAS wild type who were treated with ICI monotherapy had worse survival compared with those treated with chemoimmunotherapy (39).